BNN Stock Overview
Engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BRAIN Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.53 |
| 52 Week High | €4.40 |
| 52 Week Low | €1.42 |
| Beta | 1.2 |
| 1 Month Change | 12.06% |
| 3 Month Change | 140.14% |
| 1 Year Change | 0.28% |
| 3 Year Change | -60.69% |
| 5 Year Change | -66.44% |
| Change since IPO | -61.20% |
Recent News & Updates
Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 27% Bounce
Nov 12
Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce
Sep 24Recent updates
Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 27% Bounce
Nov 12Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce
Sep 24BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch
Aug 06Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?
Jun 29BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate
Apr 19BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable
Mar 28Is BRAIN Biotech (ETR:BNN) A Risky Investment?
Feb 16Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt
Sep 13Here's What B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shareholder Ownership Structure Looks Like
Mar 21Is B.R.A.I.N. Biotechnology Research and Information Network (ETR:BNN) Weighed On By Its Debt Load?
Feb 14When Will B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) Breakeven?
Jan 18How Much Did B.R.A.I.N. Biotechnology Research and Information Network's(ETR:BNN) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 31
Are Institutions Heavily Invested In B.R.A.I.N. Biotechnology Research and Information Network AG's (ETR:BNN) Shares?
Dec 10Should You Investigate B.R.A.I.N. Biotechnology Research and Information Network AG (ETR:BNN) At €7.30?
Nov 17Shareholder Returns
| BNN | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | -17.9% | -3.3% | -1.4% |
| 1Y | 0.3% | -8.0% | 8.0% |
Return vs Industry: BNN exceeded the German Chemicals industry which returned -8% over the past year.
Return vs Market: BNN underperformed the German Market which returned 8% over the past year.
Price Volatility
| BNN volatility | |
|---|---|
| BNN Average Weekly Movement | 25.3% |
| Chemicals Industry Average Movement | 4.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BNN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BNN's weekly volatility has increased from 14% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 319 | Aryan Moelker | www.brain-biotech.com |
BRAIN Biotech AG engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates in three segments: BioProducts, BioScience, and BioIncubator. The company offers enzymes and biocatalysts to produce food and beverages, wound care preparations or lubricants, and production of starch and bioethanol; and microorganisms as the functional biomass for optimized industrial production processes, recycling of the greenhouse gas CO2 as an industrial raw material, and urban and green mining for extraction of precious and rare earth metals.
BRAIN Biotech AG Fundamentals Summary
| BNN fundamental statistics | |
|---|---|
| Market cap | €82.37m |
| Earnings (TTM) | -€8.77m |
| Revenue (TTM) | €56.26m |
1.4x
P/S Ratio-8.8x
P/E RatioIs BNN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNN income statement (TTM) | |
|---|---|
| Revenue | €56.26m |
| Cost of Revenue | €24.98m |
| Gross Profit | €31.29m |
| Other Expenses | €40.06m |
| Earnings | -€8.77m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 15, 2025
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 55.61% |
| Net Profit Margin | -15.59% |
| Debt/Equity Ratio | 0% |
How did BNN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 19:36 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BRAIN Biotech AG is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Volker Bosse | Baader Helvea Equity Research |
| Thomas Meyer | Baader Helvea Equity Research |
| Laura Lopez Pineda | Baader Helvea Equity Research |